{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:46:23Z","timestamp":1790048783413,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Celyad S.A."},{"DOI":"10.13039\/100018985","name":"Walloon Region","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018985","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone-marrow-derived, lineage-directed, autologous cardiopoietic mesenchymal stem cells (C3BS-CQR-1) on LV remodelling in patients with advanced HF enrolled in the CHART-1 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients (n=351) with symptomatic advanced HF secondary to ischaemic heart disease, and reduced LV ejection fraction (LVEF &amp;lt;35%) were randomized to receive C3BS-CQR-1 or a sham procedure. In a post hoc analysis we examined the effect of C3BS-CQR-1 on LV reverse remodelling within 1 year of the procedure and the influence of C3BS-CQR-1 dosing in the 271 patients treated as randomized. Delivery of C3BS-CQR-1 was associated with a progressive decrease in both LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) within 52 weeks after treatment. At 1 year, the LVEDV and LVESV of treated patients decreased by 17.0 mL and 12.8 mL greater than controls (P=0.006 and P=0.017, respectively). The effect on LVEDV was maintained after multivariable adjustment for baseline age, systolic blood pressure, LVEDV, LVEF and history of myocardial infarction. The largest reverse remodelling was evident in the patients receiving a moderate number of injections (&amp;lt;20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CHART-1, intramyocardial administration of cardiopoietic stem cells led to reverse remodelling as evidenced by significant progressive decreases in LVEDV and LVESV through the 52 weeks of follow-up. Further studies are needed to explore the dose response with regard to cell number and injected volume, and reverse remodelling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.898","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T02:16:47Z","timestamp":1496197007000},"page":"1520-1529","source":"Crossref","is-referenced-by-count":101,"title":["Benefit of Cardiopoietic Mesenchymal Stem Cell Therapy on Left Ventricular Remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Study"],"prefix":"10.1093","volume":"19","author":[{"given":"John R.","family":"Teerlink","sequence":"first","affiliation":[{"name":"School of Medicine, University of California San Francisco and Section of Cardiology , San Francisco Veterans Affairs Medical Center, San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University and Spedali Civili , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos S.","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Davison","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Bartunek","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, OLV Hospital , Aalst ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Terzic","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic, Center for Regenerative Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic, Center for Regenerative Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Povsic","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute and Duke Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[{"name":"Cedars Sinai Heart Institute , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Celyad, Mont Saint Guibert \u00a0","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homsy","sequence":"additional","affiliation":[{"name":"Celyad, Mont Saint Guibert \u00a0","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Seron","sequence":"additional","affiliation":[{"name":"Celyad, Mont Saint Guibert \u00a0","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, OLV Hospital , Aalst ,","place":["Belgium"]},{"name":"The Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway and Saolta University Healthcare Group , Galway ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CHART Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"2026011721201010500_ejhf898-bib-0001","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cardfail.2016.03.017","article-title":"Pharmacologic and endovascular reversal of left ventricular remodeling","volume":"22","author":"Jaiswal","year":"2016","journal-title":"J Card Fail"},{"key":"2026011721201010500_ejhf898-bib-0002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721201010500_ejhf898-bib-0003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurjhf\/hfq113","article-title":"Cardiac remodelling and myocardial recovery: lost in translation?","volume":"12","author":"Mann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721201010500_ejhf898-bib-0004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tcm.2016.01.003","article-title":"Stem cell therapy for heart failure: ensuring regenerative proficiency","volume":"26","author":"Terzic","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"2026011721201010500_ejhf898-bib-0005","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721201010500_ejhf898-bib-0006","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ejhf.434","article-title":"Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design","volume":"18","author":"Bartunek","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721201010500_ejhf898-bib-0007","first-page":"648","article-title":"Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial","volume":"38","author":"Bartunek","year":"2017","journal-title":"Eur Heart J"},{"key":"2026011721201010500_ejhf898-bib-0008","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/hrt.2007.139394","article-title":"Cells as biologics for cardiac repair in ischaemic heart failure","volume":"96","author":"Bartunek","year":"2010","journal-title":"Heart"},{"key":"2026011721201010500_ejhf898-bib-0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCINTERVENTIONS.114.001436","article-title":"Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy","volume":"7","author":"Poglajen","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"2026011721201010500_ejhf898-bib-0010","first-page":"970","article-title":"Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model","volume":"81","author":"Kumar","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026011721201010500_ejhf898-bib-0011","first-page":"978","article-title":"Location, location, location! Is it important with cell delivery?","volume":"81","author":"Henry","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026011721201010500_ejhf898-bib-0012","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"2026011721201010500_ejhf898-bib-0013","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721201010500_ejhf898-bib-0014","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"2026011721201010500_ejhf898-bib-0015","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/eht247","article-title":"The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial","volume":"34","author":"Collier","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721201010500_ejhf898-bib-0016","doi-asserted-by":"crossref","DOI":"10.1201\/9781439821862","volume-title":"Analysis of Incomplete Multivariate Data","author":"Schafer","year":"1997"},{"key":"2026011721201010500_ejhf898-bib-0017","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2026011721201010500_ejhf898-bib-0018","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/hrt.2003.015552","article-title":"Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study","volume":"90","author":"Bellenger","year":"2004","journal-title":"Heart"},{"key":"2026011721201010500_ejhf898-bib-0019","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011721201010500_ejhf898-bib-0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"2026011721201010500_ejhf898-bib-0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"2026011721201010500_ejhf898-bib-0022","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011721201010500_ejhf898-bib-0023","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/CIRCHEARTFAILURE.114.001626","article-title":"Left ventricular reverse remodeling with biventricular versus right ventricular pacing in patients with atrioventricular block and heart failure in the BLOCK HF trial","volume":"8","author":"St John Sutton","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026011721201010500_ejhf898-bib-0024","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/eurheartj\/eht160","article-title":"REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study","volume":"34","author":"Linde","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721201010500_ejhf898-bib-0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.hrthm.2014.11.014","article-title":"The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study","volume":"12","author":"Gold","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026011721201010500_ejhf898-bib-0026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/CIRCINTERVENTIONS.112.000422","article-title":"Optimized delivery system achieves enhanced endomyocardial stem cell retention","volume":"6","author":"Behfar","year":"2013","journal-title":"Circ Cardiovasc Interv"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/11\/1520\/66327421\/eurjhf_19_11_1520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/11\/1520\/66327421\/eurjhf_19_11_1520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:22:25Z","timestamp":1768702945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/11\/1520\/8418444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,5,31]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.898","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,5,31]]}}}